Debiovision
Quick facts
Phase 3 pipeline
- Sanvar® (vapreotide) · Oncology
Vapreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and reduce symptoms in neuroendocrine tumors.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: